A similar enigma was observed for TNFR2+ tumor-infiltrating lymphocytes (TILs): TNFR2-mediated signals support the survival/activation of CD4+ T regulatory cells (Tregs) and aggravate disease course (46, 60–67); however, in triple-negative breast cancer (TNBC) patients, TNFR2+ TILs were associated with improved patient survival. This evidence concerns the gene TNFRSF1B and neoplasm.